Immunologic Factor – Page 5

CDC Advisors Shift COVID-19 Vaccine Guidance to Individual Decision-Making

1 month ago talkbio0Tagged ACIP, Centers for Disease Control and Prevention (U.S.), Consultation, COVID19 (disease), individual choice, Provider, Recommendation, Vaccines

CDC; COVID-19 vaccine; vaccine recommendation; individual choice; ACIP; provider consultation

ACIP Vote Restricts Combined MMRV Vaccine for Children Under 4, Raising Access Concerns

1 month ago talkbio0Tagged ACIP, CDC, CDC vaccine recommendation, Chickenpox, Child, Childhood, Immunization, measles, MMRV vaccine, Mumps, Rubella, vaccine access, Vaccines

ACIP; MMRV vaccine; measles; mumps; rubella; varicella; childhood immunization; Vaccines for Children (VFC) program; CDC vaccine recommendation; vaccine access

VectorY Strikes $1.2B Option and License Pact with Shape Therapeutics for Brain-Penetrant Gene Therapy Delivery

1 month ago talkbio0Tagged Alzheimer 's disease, Antibodies, biobucks, brain-penetrant delivery, Capsid, Dependovirus, gene therapy, Huntington Disease, milestone payments, Neurodegenerative Disorders, pipeline, SHP-DB1, vectorized, VectorY

VectorY Therapeutics; Shape Therapeutics; SHP-DB1; adeno-associated virus (AAV) capsid; brain-penetrant delivery; gene therapy; neurodegenerative diseases; Huntington’s disease; Alzheimer’s disease; biobucks; pipeline; milestone payments; vectorized antibodies

Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP

1 month ago talkbio0Tagged bone lesion prevention, Drugs, Orphan, fibrodysplasia, Fibrodysplasia Ossificans Progressiva, Garetosmab, Infrequent, OPTIMA trial, ossificans, Phase III, progressiva, Regeneron, Submission, United States Food and Drug Administration

Regeneron; garetosmab; FOP; fibrodysplasia ossificans progressiva; Phase III; OPTIMA trial; bone lesion prevention; rare disease; FDA submission; orphan drug

AstraZeneca’s Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment

1 month ago talkbio0Tagged anifrolumab, AstraZeneca, Clinical Trials, disease activity, Encephalitis, St. Louis, Lupus Erythematosus, Systemic, Phase III, Saphnelo, Self-Injectable, subcutaneous, TULIP-SC trial

AstraZeneca; Saphnelo; anifrolumab; Phase III; TULIP-SC trial; systemic lupus erythematosus; SLE; self-injectable; subcutaneous; clinical trial; disease activity reduction

Next-Generation Psoriasis Drugs Aim to Reshape Treatment Landscape

1 month ago talkbio0Tagged Approved, Clinical Trials, icotrokinra, inhibitors, interleukin-23, next-generation biologics, oral peptides, Piclidenoson, TYK2 gene, United States Food and Drug Administration, Vunakizumab

psoriasis; next-generation biologics; icotrokinra; IL-23 inhibitors; oral peptides; TYK2 inhibitors; vunakizumab; piclidenoson; clinical trials; FDA approval

Amgen, Kyowa Kirin Bolster Safety Profile for Atopic Dermatitis Drug Rocatinlimab

2 months ago talkbio0Tagged amgen, ASCEND trial, Dermatitis, Atopic, Eczema, Kyowa Kirin, Long-term, OX40 receptor, Programs - Publication Format, Rocatinlimab, Rocket, Safety

Amgen; Kyowa Kirin; rocatinlimab; atopic dermatitis; OX40 receptor; ASCEND trial; ROCKET program; long-term safety; eczema

Lilly Opens AI Drug-Discovery Models to Biotechs for Free via TuneLab Platform

2 months ago talkbio0Tagged Antibodies, Artificial Intelligence, biotech startups, Drug Discovery, eli lilly, federated learning, Insitro, Machine Learning, Small Molecule, TuneLab

Eli Lilly; AI drug discovery; TuneLab; biotech startups; machine learning; small molecules; antibodies; data sharing; federated learning; Insitro

Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute

2 months ago talkbio0Tagged Approved, Biosimilars, Enzeevu, Eylea, launch, Ophthalmology specialty, Patent Settlement, Regeneron, sandoz, United States, United States Food and Drug Administration

Regeneron; Sandoz; Eylea; Enzeevu; biosimilar; aflibercept; patent settlement; FDA approval; U.S. launch; ophthalmology

Novartis Acquires Tourmaline Bio for $1.4B to Bolster Cardiovascular Pipeline with Promising Phase 2 Drug

2 months ago talkbio0Tagged Acquisition, Anti-Inflammatory Agents, Antibodies, C-reactive protein, Cardiovascular Diseases, Chronic Kidney Diseases, interleukin-6, Novartis, pacibekitug, Phase 2 trial, Tourmaline Bio

Novartis; Tourmaline Bio; acquisition; $1.4 billion; pacibekitug; cardiovascular disease; anti-inflammatory; IL-6 antibody; ASCVD; phase 2 trial; C-reactive protein; chronic kidney disease